SCHEMBL5043761

SCHEMBL5043761

CCOC(=O)c1nc(-c2cc(C(=O)NCC(C)C)c(C)n2Cc2ccc(OC)cc2)cs1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 6/20 0.44
HPGD P15428 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
TP53 P04637 3/20 0.40
ALDH1A1 P00352 2/20 0.39
KLK1 P06870 2/20 0.39
MAPT P10636 2/20 0.39
LMNA P02545 2/20 0.39
GAA P10253 2/20 0.39
KDM4E B2RXH2 1/20 0.39
USP2 O75604 1/20 0.39
GLA P06280 1/20 0.39
MAPK1 P28482 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 1/20 0.39
FEN1 P39748 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6068954 0.90 ALDH1A1 (0.47) KLKB1HPGDSMN1; SMN2NPC1RAB9A
SCHEMBL5048628 0.89 HPGD (0.46) KLKB1HPGDSMN1; SMN2NPC1RAB9A
SCHEMBL5046847 0.89 ALDH1A1 (0.49) KLKB1HPGDNPC1RAB9ATP53
SCHEMBL5044556 0.89 KLKB1 (0.43) KLKB1HPGDSMN1; SMN2NPC1RAB9A
SCHEMBL5043669 0.86 KLKB1 (0.54) KLKB1HPGDSMN1; SMN2NPC1RAB9A
SCHEMBL5039254 0.84 KLKB1 (0.44) KLKB1HPGDSMN1; SMN2NPC1RAB9A
SCHEMBL5048540 0.84 ALDH1A1 (0.48) HPGDSMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL6068958 0.82 ALDH1A1 (0.41) KLKB1HPGDSMN1; SMN2NPC1RAB9A
SCHEMBL5044978 0.81 KLKB1 (0.49) KLKB1HPGDSMN1; SMN2NPC1RAB9A
SCHEMBL5044818 0.81 KLKB1 (0.48) KLKB1HPGDSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583762-B1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS HOFFMANN LA ROCHE (CH) 2008-07-09 EP disclosed
US-7135488-B2 Pyrrolyl-thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
EP-1583762-A1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-12 EP disclosed
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives HOFFMAN-LA ROCHE INC. 2004-07-29 US disclosed
WO-2004060888-A1 NOVEL CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives CNR1, CNR2, NPY1R KLKB1 3949/4885HPGD 2000/4885SMN1; SMN2 3330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.